公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2008 | Overexpression of B cell activating factor of TNF family (BAFF) is associated with Helicobacter pylori independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma | SUNG-HSIN KUO ; Yeh P.-Y.; Chen L.-T.; MING-SHIANG WU ; CHUNG-WU LIN ; KUN-HUEI YEH ; Tzeng Y.-S.; Chen J.-Y.; PING-NING HSU ; Lin J.-T.; ANN-LII CHENG | Blood | 46 | 47 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2019 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Muro K.; Van Cutsem E.; Narita Y.; Pentheroudakis G.; Baba E.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH ; Kato K.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Nakajima T.E.; Shitara K.; Kawakami H.; Tsushima T.; Yoshino T.; Lordick F.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. | Annals of Oncology | 164 | 147 | |
2019 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Muro K.; Lordick F.; Tsushima T.; Pentheroudakis G.; Baba E.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Kato K.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH ; Nakajima T.E.; Shitara K.; Kawakami H.; Narita Y.; Yoshino T.; Van Cutsem E.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. | Annals of Oncology | 104 | 90 | |
2018 | Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS | Yoshino T.; Arnold D.; Taniguchi H.; Pentheroudakis G.; Yamazaki K.; Xu R.-H.; Kim T.W.; Ismail F.; Tan I.B.; KUN-HUEI YEH ; Grothey A.; Zhang S.; Ahn J.B.; Mastura M.Y.; Chong D.; Chen L.-T.; Kopetz S.; Eguchi-Nakajima T.; Ebi H.; Ohtsu A.; Cervantes A.; Muro K.; Tabernero J.; Minami H.; Ciardiello F.; Douillard J.-Y. | Annals of Oncology | 431 | 383 | |
2015 | Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide | PO-CHIN LIANG ; Ch’ang H.-J.; CHIUN HSU ; Chen L.-T.; TIFFANY TING-FANG SHIH ; Liu T.W. | Hepatology International | 13 | 12 | |
2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. | Gastric Cancer | 138 | 130 | |
2006 | Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma | Shiah H.-S.; Chao Y.; Chen L.-T.; Yao T.-J.; Huang J.-D.; Chang J.-Y.; PEI-JER CHEN ; Chuang T.-R.; Chin Y.-H.; Whang-Peng J.; Liu T.-W. | Cancer Chemotherapy and Pharmacology | 11 | 12 | |
2021 | Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors | Shiah H.-S.; Chiang N.-J.; CHIA-CHI LIN ; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. | Oncologist | 2 | 0 | |
2006 | Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer | Ch'ang H.-J.; Wang C.-C.; ANN-LII CHENG ; CHIUN HSU ; YEN-SHEN LU ; MING-CHU CHANG ; Lin J.-T.; HSIU-PO WANG ; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 8 | 8 | |
2006 | Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer | Shiah H.-S.; ANN-LII CHENG ; CHIUN HSU ; CHIH-HUNG HSU ; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 6 | 5 | |
2011 | A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan | Chen J.-S.; Chao Y.; Hsieh R.-K.; ANN-LII CHENG ; Chen P.-M.; Chiou T.-J.; Chao T.-Y.; KUN-HUEI YEH ; Chen L.-T.; Whang-Peng J. | Cancer Chemotherapy and Pharmacology | 6 | 5 | |
2014 | Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer | Ying-Chun Shen ; Li C.-P.; Yen C.-J.; CHIUN HSU ; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH ; ANN-LII CHENG | Oncology (Switzerland) | 15 | 12 | |
2018 | Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma | Javle M.; Lowery M.; Shroff R.T.; Weiss K.H.; Springfeld C.; Borad M.J.; Ramanathan R.K.; Goyal L.; Sadeghi S.; Macarulla T.; El-Khoueiry A.; Kelley R.K.; Borbath I.; Choo S.P.; Oh D.-Y.; Philip P.A.; Chen L.-T.; Reungwetwattana T.; Van Cutsem E.; KUN-HUEI YEH ; Ciombor K.; Finn R.S.; Patel A.; Sen S.; Porter D.; Isaacs R.; Zhu A.X.; Abou-Alfa G.K.; Bekaii-Saab T. | Journal of Clinical Oncology | 511 | 428 | |
2009 | Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer | Ch'ang H.-J.; Huang C.-L.; HSIU-PO WANG ; Shiah H.-S.; MING-CHU CHANG ; Jan C.-M.; Chen J.-S.; YU-WEN TIEN ; Hwang T.-L.; Lin J.-T.; ANN-LII CHENG ; Whang-Peng J.; Chen L.-T. | Cancer Chemotherapy and Pharmacology | 13 | 13 | |
2012 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma | Ch'Ang H.-J.; CHIUN HSU ; CHIEN-HUNG CHEN ; Chang Y.-H.; Chang J.S.; Chen L.-T. | International Journal of Radiation Oncology Biology Physics | 16 | 13 | |
2004 | Promoter polymorphisms of tumor necrosis factor-α are associated with risk of gastric mucosa-associated lymphoid tissue lymphoma | MING-SHIANG WU ; Chen L.-T.; CHIA-TUNG SHUN ; Huang S.-P.; HAN-MO CHIU ; HSIU-PO WANG ; MING-TSAN LIN ; ANN-LII CHENG ; Lin J.-T. | International Journal of Cancer | 60 | 54 | |
2001 | Prospective study of Helicobacter pylori eradication therapy in stage IE high-grade mucosa-associated lymphoid tissue lymphoma of the stomach | Chen L.-T.; Lin J.-T.; Shyu R.-Y.; Jan C.-M.; Chen C.-L.; Chiang I.-P.; Liu S.-M.; Su I.-J.; ANN-LII CHENG | Journal of Clinical Oncology | 95 | 76 | |
2010 | A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients | Yang T.-S.; Lu S.-N.; Chao Y.; Sheen I.-S.; Lin C.-C.; Wang T.-E.; Chen S.-C.; Wang J.-H.; Liao L.-Y.; Thomson J.A.; Wang-Peng J.; PEI-JER CHEN ; Chen L.-T. | British Journal of Cancer | 134 | 124 | |
2010 | Role of histone deacetylases HDA6 and HDA19 in ABA and abiotic stress response | Chen L.-T.; Wu K. | Plant Signaling and Behavior | 166 | 0 | |